However, when cannabinoids are taken externally, it’s difficult to distinguish between the clinically desirable effects and the therapeutically undesirable effects of various phytocannabinoids. This is because cannabinoid receptors send a variety of signals that often interconnect to coordinate the body’s functions, so it’s hard to tell them apart.
When taken by mouth: Cannabidiol is POSSIBLY SAFE when taken by mouth or sprayed under the tongue appropriately. Cannabidiol in doses of up to 300 mg daily have been taken by mouth safely for up to 6 months. Higher doses of 1200-1500 mg daily have been taken by mouth safely for up to 4 weeks. A prescription cannabidiol product (Epidiolex) is approved to be taken by mouth in doses of up to 10-20 mg/kg daily. Cannabidiol sprays that are applied under the tongue have been used in doses of 2.5 mg for up to 2 weeks.
The passage of the 2018 Farm Bill made it legal to sell hemp and hemp products in the U.S. But that doesn't mean that all hemp-derived cannabidiol products are legal. Since cannabidiol has been studied as a new drug, it can't be legally included in foods or dietary supplements. Also, cannabidiol can't be included in products marketed with therapeutic claims. Cannabidiol can only be included in "cosmetic" products and only if it contains less than 0.3% THC. But there are still products labeled as dietary supplements on the market that contain cannabidiol. The amount of cannabidiol contained in these products is not always reported accurately on the product label. cbd oil
^ Jump up to: a b c Devinsky, Orrin; Cilio, Maria Roberta; Cross, Helen; Fernandez-Ruiz, Javier; French, Jacqueline; Hill, Charlotte; Katz, Russell; Di Marzo, Vincenzo; Jutras-Aswad, Didier; Notcutt, William George; Martinez-Orgado, Jose; Robson, Philip J.; Rohrback, Brian G.; Thiele, Elizabeth; Whalley, Benjamin; Friedman, Daniel (May 22, 2014). "Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
^ Jump up to: a b c Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (September 6, 2017). "Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol". Neuropsychopharmacology. 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.
^ Jump up to: a b c "FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety". US Food and Drug Administration. July 23, 2019. Retrieved July 24, 2019. Unlike drugs approved by the FDA, the manufacturing process of these products has not been subject to FDA review as part of the drug approval process, and there has been no FDA evaluation of whether these products are effective for their intended use, what the proper dosage is, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns.
Schizophrenia. Research on the use of cannabidiol for psychotic symptoms in people with schizophrenia is conflicting. Some early research suggests that taking cannabidiol four times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic medication amisulpride. However, other early research suggests that taking cannabidiol for 14 days is not beneficial. The conflicting results might be related to the cannabidiol dose used and duration of treatment. cannabidiol oil